Back to Newsroom

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015

CARLSBAD, CA–(Marketwired – November 16, 2015) – International Stem Cell Corporation (OTCQB: ISCO) ( (“ISCO” or “the Company”), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2015.

“Overall I am satisfied with the Company’s progress in Q3. We are maintaining our position as a leader in regenerative medicine field and the overall operating income of our biomedical businesses continues to grow,” said Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO. “We really look forward to beginning the enrolment of patients in our pending Parkinson’s Disease clinical trial before the end of 2015.”

Click here to read more